Celltrion said on the 7th that it recently introduced Zymfentra at the American Gastroenterological Association meeting. Zymfentra is a subcutaneous (SC) formulation of Remsima, a biosimilar of Remicade, an autoimmune disease treatment.
Celltrion released results from the global phase 3 trial of Zymfentra at the meeting. The study targeted patients with Crohn's disease and ulcerative colitis. In patients who discontinued intravenous (IV) treatment, administering 240 mg of Zymfentra maintained strong efficacy through week 102. The company said the findings suggest it can help patients who experience treatment gaps.
It also released 44-week results from a phase 3 trial of Zymfentra in Japan in patients with Crohn's disease. In patients who had achieved remission (a state in which the disease is nearly absent) on intravenous therapy, switching to subcutaneous injections maintained safety and efficacy. The company also held product briefings under the theme "Understanding Zymfentra."
Zymfentra posted global sales of 839.4 billion won last year. It is targeting 1 trillion won in sales this year. A Celltrion official said the company will pursue "differentiated, tailored marketing."